NEW YORK, Jan. 20, 2017 /PRNewswire/ -- The number of Taxotere lawsuit filings involving the cancer drug's alleged potential to cause permanent alopecia surged this month in the centralized litigation now underway in the U.S. District Court, Eastern District of Louisiana. According to an updated docket report issued by the U.S. Judicial Panel on Multidistrict Litigation on January 17th, there are now 705 claims pending in the proceeding. That figure indicates that at least 443 new Taxotere cases have either been transferred to or filed in the Eastern District of Louisiana since December 16, 2016, when just 262 pending claims were reported. (In Re: Taxotere (Docetaxal) Products Liability Litigation - MDL No. 2740)
The Taxotere litigation continues to move forward, as the Court's calendar indicates it will convene a Status Conference next Thursday, January 26th at 10:00 a.m. CST. The Conference will be preceded by a meeting of liaison counsel at 8:45 a.m., and a meeting of the Plaintiffs Steering Committee at 9:00 a.m.
"Our Firm has heard from numerous individuals whose hair allegedly failed to grow back following chemotherapy with Taxotere. We are not at all surprised that the number of cases pending in the federal litigation has increased at a fairly significant rate," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is now offering free case reviews to breast cancer patients and others who experienced permanent hair loss allegedly associated with Taxotere cancer treatment.
Taxotere and Permanent Hair Loss
Taxotere was approved for sale in the U.S. in 1996, and is now indicated to treat breast cancer, head and neck cancer, gastric cancer, prostate cancer and non-small cell lung cancer. It was only in December 2015 that the drug's U.S. label was updated to note that cases of permanent hair loss had been reported among some patients treated with Taxotere. However, plaintiffs point out that Sanofi-Aventis has long provided information regarding the potential for permanent alopecia to individual patients and regulatory agencies overseas. They question why U.S. patients and doctors were only provided with a "generic, vague and insufficient" warning that "hair generally grows back."
Cancer patients who allegedly experienced permanent hair loss following chemotherapy with Taxotere may be entitled to compensation for their emotional distress and other damages. To learn more about filing a Taxotere lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
SOURCE Bernstein Liebhard LLP